1 |
11c-acetate |
Acetate |
- |
- |
- |
013 [3] 13, 86, 88 💬 |
2 |
20mg/0.5ml glatiramer acetate |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
3 |
40 mg glatiramer acetate |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
002 [2] 2 , 13 💬 |
4 |
40 mg glatiramer acetato |
Glatiramer |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
5 |
5% lidocaine/5 mg/ml 0.02% estradiol compound cream |
Estradiol |
[11] D00105 D00105, D00358 D00358, D01413 D01413, D01617 D01617, D01953 D01953, D02086 D02086, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065, D08127 D08127 💬 |
ESR1 [7] ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [12] Adrenergic signaling in cardiomyocytes, Breast cancer, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway |
226 [1] 226 💬 |
6 |
90 mg hydrocortisone acetate suppository with sephure suppository applicator |
Acetate |
[2] D00088 D00088, D00165 D00165 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
7 |
[n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate |
Acetate |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
265 [1] 265 💬 |
8 |
Abiraterone |
Abiraterone |
[1] D09701 D09701 💬 |
- |
- |
075 [2] 75, 81 💬 |
9 |
Abiraterone acetate |
Abiraterone |
[1] D09701 D09701 💬 |
- |
- |
075 [2] 75, 81 💬 |
10 |
Acetate |
Acetate |
- |
- |
- |
001 [43] 1 , 2 , 6 , 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299 💬 |
11 |
Administration of rituximab and methylprednisolone |
Methylprednisolone |
[7] D00407 D00407, D00751 D00751, D00979 D00979, D02994 D02994, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
MS4A1 [2] MS4A1, NR3C1 💬 |
Hematopoietic cell lineage [2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction |
051 [1] 51 💬 |
12 |
Azd4017 and prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
075 [1] 75 💬 |
13 |
Bazedoxifene |
Bazedoxifene |
[1] D03062 D03062 💬 |
- |
- |
013 [1] 13 💬 |
14 |
Bazedoxifene acetate |
Acetate |
[1] D03062 D03062 💬 |
- |
- |
013 [1] 13 💬 |
15 |
Betamethasone |
Betamethasone |
[7] D00244 D00244, D00972 D00972, D01357 D01357, D01402 D01402, D01637 D01637, D02032 D02032, D02286 D02286 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [6] 2 , 28, 46, 90, 96, 235 💬 |
16 |
Betamethasone acibutate |
Betamethasone |
[7] D00244 D00244, D00972 D00972, D01357 D01357, D01402 D01402, D01637 D01637, D02032 D02032, D02286 D02286 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
17 |
Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days |
Acetate |
[7] D00244 D00244, D00972 D00972, D01357 D01357, D01402 D01402, D01637 D01637, D02032 D02032, D02286 D02286 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [1] 2 💬 |
18 |
Bortezomib/dexamethasone |
Bortezomib |
[10] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D03150 D03150 💬 |
NR3C1 [2] NR3C1, PSMB5 💬 |
Alzheimer disease [9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
283 [1] 283 💬 |
19 |
Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone |
Bortezomib |
[10] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D03150 D03150 💬 |
NR3C1 [2] NR3C1, PSMB5 💬 |
Alzheimer disease [9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
028 [1] 28 💬 |
20 |
Bupivacaine/epinephrine/dexamethasone |
Bupivacaine |
[14] D00095 D00095, D00292 D00292, D00975 D00975, D00996 D00996, D01450 D01450, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02149 D02149, D02174 D02174, D02591 D02591, D02592 D02592, D07552 D07552 💬 |
ADRA1A [15] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
AMPK signaling pathway [15] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
096 [1] 96 💬 |
21 |
Caspofungin |
Caspofungin |
[2] D02501 D02501, D07626 D07626 💬 |
- |
- |
060 [1] 60 💬 |
22 |
Caspofungin acetate |
Acetate |
[2] D02501 D02501, D07626 D07626 💬 |
- |
- |
060 [1] 60 💬 |
23 |
Cetrorelix |
Cetrorelix |
[2] D01685 D01685, D07665 D07665 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
24 |
Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine |
Azathioprine |
[12] D00238 D00238, D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D02994 D02994, D03033 D03033 💬 |
MS4A1 [2] MS4A1, NR3C1 💬 |
Hematopoietic cell lineage [2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction |
035 [1] 35 💬 |
25 |
Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator |
Acetate |
[2] D00088 D00088, D00165 D00165 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
26 |
Combination therapy with vigabatrin and prednisolone |
Prednisolone |
[9] D00472 D00472, D00535 D00535, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
ABAT [2] ABAT, NR3C1 💬 |
Alanine, aspartate and glutamate metabolism [8] Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
145 [1] 145 💬 |
27 |
Control intervention (no dexamethasone) |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
28 |
Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) |
Acetate |
[21] D00088 D00088, D00292 D00292, D00472 D00472, D00473 D00473, D00973 D00973, D00975 D00975, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D01998 D01998, D02156 D02156, D02174 D02174, D02591 D02591, D02592 D02592, D03301 D03301, D07749 D07749 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
29 |
Corticosteroid (prednisolone) |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
085 [1] 85 💬 |
30 |
Corticosteroid treatment (methylprednisolone or prednisolone) |
Methylprednisolone |
[14] D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
064 [1] 64 💬 |
31 |
Corticosteroids (prednisone or prednisolone) |
Prednisolone |
[9] D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
049 [1] 49 💬 |
32 |
Cortisone acetate |
Acetate |
[2] D00973 D00973, D07749 D07749 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
33 |
Cosyntropin acetate |
Acetate |
[1] D00284 D00284 💬 |
MC2R [1] MC2R 💬 |
Aldosterone synthesis and secretion [5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
113 [1] 113 💬 |
34 |
Cyclophosphamide, azathioprine,prednisone,methylprednisolone |
Azathioprine |
[11] D00238 D00238, D00287 D00287, D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D03033 D03033, D05000 D05000, D05001 D05001, D05002 D05002, D07760 D07760 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
042 [3] 42, 43, 45 💬 |
35 |
Cyclophosphamide, bortezomib, and dexamethasone (cybord) |
Bortezomib |
[12] D00287 D00287, D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D03150 D03150, D07760 D07760 💬 |
NR3C1 [2] NR3C1, PSMB5 💬 |
Alzheimer disease [9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
028 [1] 28 💬 |
36 |
Cyclophosphamide, bortezomib, dexamethasone |
Bortezomib |
[12] D00287 D00287, D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D03150 D03150, D07760 D07760 💬 |
NR3C1 [2] NR3C1, PSMB5 💬 |
Alzheimer disease [9] Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
028 [1] 28 💬 |
37 |
Cyclophosphamide, bortezomib, dexamethasone plus daratumumab |
Bortezomib |
[13] D00287 D00287, D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D03150 D03150, D07760 D07760, D10777 D10777 💬 |
CD38 [3] CD38, NR3C1, PSMB5 💬 |
Alzheimer disease [16] Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Hematopoietic cell lineage, Huntington disease, Metabolic pathways, Neuroactive ligand-receptor interaction, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Salivary secretion, Spinocerebellar ataxia |
028 [1] 28 💬 |
38 |
Cyclophosphamide/glatiramer acetate |
Acetate |
[3] D00287 D00287, D04318 D04318, D07760 D07760 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
39 |
Ddavp (desmopressin) |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
288 [1] 288 💬 |
40 |
Delmitide acetate |
Acetate |
- |
- |
- |
097 [1] 97 💬 |
41 |
Depot leuprolide acetate 3.75 mg |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
051 [1] 51 💬 |
42 |
Desmopressin |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 [5] 6 , 64, 72, 225, 288 💬 |
43 |
Desmopressin acetat |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 [1] 6 💬 |
44 |
Desmopressin acetate |
Acetate |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
064 [2] 64, 288 💬 |
45 |
Desmopressin acetate trihydrate |
Acetate |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
225 [1] 225 💬 |
46 |
Desmopressin intranasal |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
072 [1] 72 💬 |
47 |
Desmopressin oral melt |
Desmopressin |
[2] D00291 D00291, D02235 D02235 💬 |
AVPR2 [2] AVPR2, F8 💬 |
Complement and coagulation cascades [4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
072 [1] 72 💬 |
48 |
Device: cellulose acetate with petrolatum |
Acetate |
[3] D00093 D00093, D05304 D05304, D05331 D05331 💬 |
- |
- |
035 [2] 35, 162 💬 |
49 |
Device: dexamethasone injection |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
090 [1] 90 💬 |
50 |
Dexamethasone |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 162, 222, 235, 283, 296, 299 💬 |
51 |
Dexamethasone (1 cycle) |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
063 [1] 63 💬 |
52 |
Dexamethasone (4 cycles) |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
063 [1] 63 💬 |
53 |
Dexamethasone (50mg 1dd6, 3 consecutive days/month) |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
035 [1] 35 💬 |
54 |
Dexamethasone 0,1 mg tablets |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
55 |
Dexamethasone 0,5mg |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
084 [1] 84 💬 |
56 |
Dexamethasone 0.5mg tablet |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
57 |
Dexamethasone 0.5mg/5ml solution |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
035 [2] 35, 162 💬 |
58 |
Dexamethasone 0.5mg/5ml solution in mucolox™ |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
035 [2] 35, 162 💬 |
59 |
Dexamethasone 1,5 mg tablets |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
60 |
Dexamethasone 21-dihydrogen phosphate |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [1] 65 💬 |
61 |
Dexamethasone 21-phosphate |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
62 |
Dexamethasone 2mg tablets |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
63 |
Dexamethasone 4 mg jenapharm |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
028 [1] 28 💬 |
64 |
Dexamethasone abcur |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
063 [1] 63 💬 |
65 |
Dexamethasone and rituximab |
Dexamethasone |
[10] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D02994 D02994 💬 |
MS4A1 [2] MS4A1, NR3C1 💬 |
Hematopoietic cell lineage [2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction |
063 [1] 63 💬 |
66 |
Dexamethasone oral tablet 8mg (dexamethasone krka tablets(8mg), warsaw, poland). |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
235 [1] 235 💬 |
67 |
Dexamethasone parotid irrigation |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
053 [1] 53 💬 |
68 |
Dexamethasone sodium phosphate |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [3] 65, 70, 96 💬 |
69 |
Dexamethasone sodium phosphate 250 mg/ 10 ml |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
096 [1] 96 💬 |
70 |
Dexamethasone sodium phosphate 250 mg/10 ml solution |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
299 [1] 299 💬 |
71 |
Dexamethasone sodium phosphate ph. eur. |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [1] 65 💬 |
72 |
Dexamethasone sodium sulfate |
Dexamethasone |
[11] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01732 D01732, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D05877 D05877 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
028 [1] 28 💬 |
73 |
Dexamethasone soduim phosphate |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
74 |
Dexamethasone, 40 mg |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
028 [1] 28 💬 |
75 |
Diagnostic test: dexamethasone test |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
075 [1] 75 💬 |
76 |
Dirucotide acetate |
Acetate |
[1] D09396 D09396 💬 |
- |
- |
013 [1] 13 💬 |
77 |
Edratide acetate |
Acetate |
[1] D03957 D03957 💬 |
- |
- |
049 [1] 49 💬 |
78 |
Estradiol |
Estradiol |
[8] D00105 D00105, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
013 [5] 13, 46, 49, 226, 299 💬 |
79 |
Estradiol 2 mg |
Estradiol |
[8] D00105 D00105, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
299 [1] 299 💬 |
80 |
Estradiol hemihydrate |
Estradiol |
[8] D00105 D00105, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
013 [1] 13 💬 |
81 |
Etanercept, methotrexate, prednisolone |
Etanercept |
[11] D00142 D00142, D00472 D00472, D00742 D00742, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02115 D02115, D02156 D02156, D03301 D03301 💬 |
DHFR [5] DHFR, DHFR2, LTA, NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [70] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
056 [1] 56 💬 |
82 |
Ethinyl estradiol |
Estradiol |
[9] D00105 D00105, D00554 D00554, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
046 [3] 46, 49, 299 💬 |
83 |
Experimental glatiramer acetate |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
84 |
Flecainide |
Flecainide |
[2] D00638 D00638, D07962 D07962 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 [1] 6 💬 |
85 |
Flecainide acetate |
Acetate |
[2] D00638 D00638, D07962 D07962 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 [1] 6 💬 |
86 |
Fludrocortisone |
Fludrocortisone |
[2] D00986 D00986, D07967 D07967 💬 |
NR3C2 [1] NR3C2 💬 |
Aldosterone-regulated sodium reabsorption [1] Aldosterone-regulated sodium reabsorption |
006 [3] 6 , 17, 81 💬 |
87 |
Gallium-68-dota-n-octreotide |
Octreotide |
[2] D00442 D00442, D06495 D06495 💬 |
SSTR2 [1] SSTR2 💬 |
Gastric acid secretion [4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
084 [1] 84 💬 |
88 |
Glatiramer |
Glatiramer |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
002 [4] 2 , 13, 96, 156 💬 |
89 |
Glatiramer acetate |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [3] 13, 96, 156 💬 |
90 |
Glatiramer acetate (copaxone®) |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [2] 13, 156 💬 |
91 |
Glatiramer acetate (db) |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
92 |
Glatiramer acetate (ga) |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
93 |
Glatiramer acetate (ga) 40 mg |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
94 |
Glatiramer acetate (gtr) |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
95 |
Glatiramer acetate (ol) |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
96 |
Glatiramer acetate 150mg enteric coated tablets |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
97 |
Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
98 |
Glatiramer acetate 20 mg |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
99 |
Glatiramer acetate 20 mg, with mitoxantrone |
Acetate |
[3] D02166 D02166, D04318 D04318, D08224 D08224 💬 |
HLA-A [22] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, TOP2A, TOP2B 💬 |
Allograft rejection [33] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Platinum drug resistance, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
100 |
Glatiramer acetate 20 mg/0.5 ml |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
101 |
Glatiramer acetate 40 mg |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
102 |
Glatiramer acetate [ga] |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
103 |
Glatiramer acetate injection with oral cetirizine hydrochloride |
Acetate |
[3] D00664 D00664, D04318 D04318, D07662 D07662 💬 |
HLA-A [21] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, HRH1 💬 |
Allograft rejection [35] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Calcium signaling pathway, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
104 |
Glatiramer acetate with minocycline |
Acetate |
[3] D00850 D00850, D04318 D04318, D05045 D05045 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
105 |
Glatiramer acetate, (copaxone®) |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
106 |
Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
107 |
Glatiramer acetate, n-acetylcysteine |
Acetate |
[2] D00221 D00221, D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
108 |
Glatiramer acetato |
Glatiramer |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
109 |
Glucocorticoid (prednisone or prednisolone) |
Prednisolone |
[9] D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
084 [1] 84 💬 |
110 |
Gonadorelin |
Gonadorelin |
[4] D00988 D00988, D03267 D03267, D04361 D04361, D08027 D08027 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
111 |
Gonadorelin acetate and triptorelin acetate |
Acetate |
[5] D00988 D00988, D03267 D03267, D04361 D04361, D06247 D06247, D08027 D08027 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
112 |
Goserelin |
Goserelin |
[2] D00573 D00573, D04405 D04405 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
001 [1] 1 💬 |
113 |
Hematide, peginesatide |
Peginesatide |
[2] D09946 D09946, D09947 D09947 💬 |
EPOR [1] EPOR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
283 [1] 283 💬 |
114 |
High dose dexamethasone pulses |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
063 [1] 63 💬 |
115 |
Human interferon beta-1a and glatiramer acetate |
Acetate |
[2] D04318 D04318, D04554 D04554 💬 |
HLA-A [22] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, IFNAR1, IFNAR2 💬 |
Allograft rejection [44] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
116 |
Hydrocortisone acetate |
Acetate |
[2] D00088 D00088, D00165 D00165 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
117 |
Hydrocortisone sodium acetate |
Acetate |
[2] D00088 D00088, D01779 D01779 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
118 |
Hydroxocobalamin |
Hydroxocobalamin |
[3] D01027 D01027, D02707 D02707, D04929 D04929 💬 |
- |
- |
097 [1] 97 💬 |
119 |
Hydroxocobalamin with butyrate |
Butyric Acid |
[4] D01027 D01027, D02707 D02707, D04929 D04929, D05866 D05866 💬 |
- |
- |
097 [1] 97 💬 |
120 |
Infliximab, methylprednisolone, methotrexate |
Infliximab |
[9] D00142 D00142, D00407 D00407, D00751 D00751, D00979 D00979, D02115 D02115, D02598 D02598, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
DHFR [4] DHFR, DHFR2, NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [70] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
121 |
Interferon-beta-1a (avonex) plus methylprednisolone |
Human interferon beta |
[7] D00407 D00407, D00751 D00751, D00979 D00979, D04554 D04554, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
IFNAR1 [3] IFNAR1, IFNAR2, NR3C1 💬 |
Coronavirus disease - COVID-19 [19] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 [1] 13 💬 |
122 |
Intra-articular compound betamethasone |
Betamethasone |
[7] D00244 D00244, D00972 D00972, D01357 D01357, D01402 D01402, D01637 D01637, D02032 D02032, D02286 D02286 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
123 |
Intraarticular betamethasone |
Betamethasone |
[7] D00244 D00244, D00972 D00972, D01357 D01357, D01402 D01402, D01637 D01637, D02032 D02032, D02286 D02286 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
124 |
Intraarticular dexamethasone |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
125 |
Intravenous (i.v.) methylprednisolone 1000 mg, total 9 |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
222 [1] 222 💬 |
126 |
Intravenous dexamethasone 1 mg |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
127 |
Intravenous methyl prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
043 [1] 43 💬 |
128 |
Intravenous methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [2] 13, 145 💬 |
129 |
Iv methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
130 |
Iv methylprednisolone (steroids) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
131 |
L-lysyl-d-prolyl-l-threonine acetate |
Acetate |
[1] D00041 D00041 💬 |
- |
- |
097 [1] 97 💬 |
132 |
L-lysyl-d-prolyl-lthreonine acetate, lyophilisate |
Acetate |
- |
- |
- |
097 [1] 97 💬 |
133 |
Lanreotide |
Lanreotide |
[1] D04666 D04666 💬 |
- |
- |
067 [4] 67, 73, 85, 298 💬 |
134 |
Lanreotide acetate |
Acetate |
[1] D04666 D04666 💬 |
- |
- |
067 [4] 67, 73, 85, 298 💬 |
135 |
Lapaquistat acetate and current lipid-lowering treatment |
Acetate |
- |
- |
- |
079 [1] 79 💬 |
136 |
Lenalidomide and dexamethasone |
Dexamethasone |
[10] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D04687 D04687 💬 |
NR3C1 [2] NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
016 [1] 16 💬 |
137 |
Lenalidomide+dexamethasone |
Dexamethasone |
[10] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D04687 D04687 💬 |
NR3C1 [2] NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
016 [1] 16 💬 |
138 |
Lenalidomide, dexamethasone |
Dexamethasone |
[10] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D04687 D04687 💬 |
NR3C1 [2] NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
016 [1] 16 💬 |
139 |
Lenalidomide, dexamethasone and cyclophosphamide |
Cyclophosphamide |
[12] D00287 D00287, D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D04687 D04687, D07760 D07760 💬 |
NR3C1 [2] NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
028 [1] 28 💬 |
140 |
Leuprolide |
Leuprolide |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
001 [5] 1 , 2 , 3 , 51, 76 💬 |
141 |
Leuprolide (gnrh agonists) |
Gonadorelin |
[6] D00988 D00988, D00989 D00989, D03267 D03267, D04361 D04361, D08027 D08027, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
142 |
Leuprolide acetate (la) |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
143 |
Leuprolide acetate 11.25 mg |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
144 |
Leuprolide acetate 3 month depot |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
145 |
Leuprolide acetate 30 mg |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
146 |
Leuprolide acetate 45 mg |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
147 |
Leuprolide acetate depot |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
148 |
Leuprorelin acetate |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
001 [2] 1 , 76 💬 |
149 |
Leuprorelin acetate 3.75mg injection |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
150 |
Lodotra (delayed release prednisolone) |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
041 [1] 41 💬 |
151 |
Loestrin (norethindrone acetate and ethinyl estradiol) |
Acetate |
[11] D00105 D00105, D00182 D00182, D00554 D00554, D00953 D00953, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [3] ESR1, ESR2, PGR 💬 |
Breast cancer [11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
299 [1] 299 💬 |
152 |
Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) |
Acetate |
[11] D00105 D00105, D00182 D00182, D00554 D00554, D00953 D00953, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [3] ESR1, ESR2, PGR 💬 |
Breast cancer [11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
046 [2] 46, 49 💬 |
153 |
Long-circulating liposomal prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
154 |
Low dose prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
084 [1] 84 💬 |
155 |
Luphere depot 3.75mg(leuprolide acetate 3.75mg) |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
156 |
Lupron (leuprolide acetate) |
Acetate |
[2] D00989 D00989, D08113 D08113 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
157 |
Macimorelin acetate |
Acetate |
[1] D10563 D10563 💬 |
GHSR [1] GHSR 💬 |
Growth hormone synthesis, secretion and action [3] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
078 [1] 78 💬 |
158 |
Medium dose prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
084 [1] 84 💬 |
159 |
Megadose oral methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
160 |
Megestrol acetate |
Acetate |
[2] D00952 D00952, D08167 D08167 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
076 [1] 76 💬 |
161 |
Megestrol acetate tablet |
Acetate |
[2] D00952 D00952, D08167 D08167 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
076 [1] 76 💬 |
162 |
Melphalan, thalidomide and dexamethasone |
Dexamethasone |
[11] D00292 D00292, D00369 D00369, D00754 D00754, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [2] NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
028 [1] 28 💬 |
163 |
Methotrexate + methylprednisolone |
Methotrexate |
[8] D00142 D00142, D00407 D00407, D00751 D00751, D00979 D00979, D02115 D02115, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
DHFR [3] DHFR, DHFR2, NR3C1 💬 |
Antifolate resistance [6] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate |
046 [1] 46 💬 |
164 |
Methotrexate - etanercept - prednisolone arm |
Etanercept |
[11] D00142 D00142, D00472 D00472, D00742 D00742, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02115 D02115, D02156 D02156, D03301 D03301 💬 |
DHFR [5] DHFR, DHFR2, LTA, NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [70] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
165 |
Methyl prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
043 [3] 43, 49, 96 💬 |
166 |
Methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [44] 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
167 |
Methylprednisolone (drug) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
168 |
Methylprednisolone (mp) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
060 [2] 60, 285 💬 |
169 |
Methylprednisolone (mp) or prednisone (pred) |
Methylprednisolone |
[7] D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
170 |
Methylprednisolone (or other glucocorticoid) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
043 [1] 43 💬 |
171 |
Methylprednisolone (solu-medrol) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
014 [1] 14 💬 |
172 |
Methylprednisolone 1250 mg/24h x3 days |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
173 |
Methylprednisolone acetate |
Acetate |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
051 [1] 51 💬 |
174 |
Methylprednisolone bolus iv 15 mg/kg/d for 3 days. |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
084 [1] 84 💬 |
175 |
Methylprednisolone hemisuccinate |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
176 |
Methylprednisolone iv |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
177 |
Methylprednisolone mylan générique |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
178 |
Methylprednisolone or budesonide |
Budesonide |
[7] D00246 D00246, D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
096 [1] 96 💬 |
179 |
Methylprednisolone or prednisolone |
Methylprednisolone |
[14] D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [1] 65 💬 |
180 |
Methylprednisolone po |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
181 |
Methylprednisolone pulse |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [2] 66, 220 💬 |
182 |
Methylprednisolone sodium hemisuccinate |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [2] 13, 97 💬 |
183 |
Methylprednisolone sodium succinate |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [6] 13, 46, 49, 50, 51, 211 💬 |
184 |
Methylprednisolone(intravenously in the 1st-2nd-3rd month ) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
185 |
Methylprednisolone(intravenously in the 1st-3rd-5th month) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
186 |
Mmf and dexamethasone |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
222 [1] 222 💬 |
187 |
Nomegestrol acetate |
Acetate |
[2] D07222 D07222, D08281 D08281 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 [1] 13 💬 |
188 |
Octreotide |
Octreotide |
[2] D00442 D00442, D06495 D06495 💬 |
SSTR2 [1] SSTR2 💬 |
Gastric acid secretion [4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
067 [7] 67, 75, 84, 85, 89, 193, 227 💬 |
189 |
Octreotide acetate |
Acetate |
[2] D00442 D00442, D06495 D06495 💬 |
SSTR2 [1] SSTR2 💬 |
Gastric acid secretion [4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
227 [1] 227 💬 |
190 |
Octreotide lar |
Octreotide |
[2] D00442 D00442, D06495 D06495 💬 |
SSTR2 [1] SSTR2 💬 |
Gastric acid secretion [4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
067 [2] 67, 227 💬 |
191 |
Octreotide lar / sandostatin lar (lar=long acting release) |
Octreotide |
[2] D00442 D00442, D06495 D06495 💬 |
SSTR2 [1] SSTR2 💬 |
Gastric acid secretion [4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
084 [1] 84 💬 |
192 |
Octreotide-lar |
Octreotide |
[2] D00442 D00442, D06495 D06495 💬 |
SSTR2 [1] SSTR2 💬 |
Gastric acid secretion [4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
067 [1] 67 💬 |
193 |
Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone |
Mesalazine |
[7] D00377 D00377, D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
194 |
Oral methylprednisolone 625 mg/24h x3 days |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
195 |
Oral prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
049 [2] 49, 145 💬 |
196 |
Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg |
Estradiol |
[10] D00105 D00105, D00554 D00554, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065, D05209 D05209 💬 |
ESR1 [3] ESR1, ESR2, PGR 💬 |
Breast cancer [11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
299 [1] 299 💬 |
197 |
Overencapsulated prednisolone tablets |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
198 |
Paroxetine & prednisolone |
Paroxetine |
[12] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 [2] NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 [1] 46 💬 |
199 |
Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp |
Paroxetine |
[12] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 [2] NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 [1] 46 💬 |
200 |
Paroxetine hydrochloride tablets 10 & 20 mg and prednisolone 1 mg bp |
Paroxetine |
[12] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 [2] NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 [1] 46 💬 |
201 |
Peg-liposomal prednisolone sodium phosphate |
Phosphate ion |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [2] 13, 97 💬 |
202 |
Peginesatide |
Peginesatide |
[2] D09946 D09946, D09947 D09947 💬 |
EPOR [1] EPOR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
283 [1] 283 💬 |
203 |
Peri-neural dexamethasone 1 mg |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
204 |
Phosphate and betamethasone acetate, 2 ml. |
Acetate |
[7] D00244 D00244, D00972 D00972, D01357 D01357, D01402 D01402, D01637 D01637, D02032 D02032, D02286 D02286 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
235 [1] 235 💬 |
205 |
Plovamer acetate |
Acetate |
- |
- |
- |
013 [1] 13 💬 |
206 |
Plovamer acetate 0.5 milligram (mg) |
Acetate |
- |
- |
- |
013 [1] 13 💬 |
207 |
Plovamer acetate 10 mg |
Acetate |
- |
- |
- |
013 [1] 13 💬 |
208 |
Plovamer acetate 20 mg |
Acetate |
- |
- |
- |
013 [1] 13 💬 |
209 |
Plovamer acetate 3 mg |
Acetate |
- |
- |
- |
013 [1] 13 💬 |
210 |
Pomalidomide and dexamethasone |
Dexamethasone |
[10] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D08976 D08976 💬 |
IL6 [3] IL6, NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [79] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
028 [1] 28 💬 |
211 |
Prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
011 [40] 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 |
212 |
Prednisolone & dipyridamole |
Dipyridamole |
[9] D00302 D00302, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [3] NR3C1, PDE4A, PDE5A 💬 |
Metabolic pathways [7] Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 [1] 46 💬 |
213 |
Prednisolone + mabthera |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
061 [1] 61 💬 |
214 |
Prednisolone 1mg tablets |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
215 |
Prednisolone 2,5 mg tablets |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
216 |
Prednisolone 20 mg |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
217 |
Prednisolone 40 mg |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
218 |
Prednisolone 5 mg |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [2] 46, 51 💬 |
219 |
Prednisolone 5 mg jenapharm |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
041 [1] 41 💬 |
220 |
Prednisolone 5 mg tablets |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
221 |
Prednisolone 5mg gastro-resistant tablets |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
051 [1] 51 💬 |
222 |
Prednisolone 5mg tablet |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
081 [1] 81 💬 |
223 |
Prednisolone acetate |
Acetate |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
222 [1] 222 💬 |
224 |
Prednisolone and chlorambucil |
Chlorambucil |
[9] D00266 D00266, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
222 [1] 222 💬 |
225 |
Prednisolone and mycophenolate mofetil |
Mycophenolate mofetil |
[12] D00472 D00472, D00752 D00752, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 [3] IMPDH1, IMPDH2, NR3C1 💬 |
Drug metabolism - other enzymes [4] Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism |
222 [1] 222 💬 |
226 |
Prednisolone and taper |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
051 [1] 51 💬 |
227 |
Prednisolone labesfal |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
228 |
Prednisolone sodium metasulphobenzoate |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
229 |
Prednisolone sodium phosphate |
Phosphate ion |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [2] 13, 97 💬 |
230 |
Prednisolone sodium succinate |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
095 [1] 95 💬 |
231 |
Prednisolone tablets b.p. 5mg |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
232 |
Prednisolone tablets bp |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
233 |
Prednisolone tablets bp 1 mg |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
234 |
Prednisolone tablets usp 5 mg |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
235 |
Prednisolone-dipyridamole |
Dipyridamole |
[9] D00302 D00302, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [3] NR3C1, PDE4A, PDE5A 💬 |
Metabolic pathways [7] Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 [1] 46 💬 |
236 |
Prednisolone/prednisone |
Prednisolone |
[9] D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
049 [1] 49 💬 |
237 |
Prednisone (and methylprednisolone) |
Methylprednisolone |
[7] D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
043 [1] 43 💬 |
238 |
Prednisone acetate |
Acetate |
[2] D00473 D00473, D08416 D08416 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
040 [3] 40, 49, 224 💬 |
239 |
Prednisone acetate tablets |
Acetate |
[2] D00473 D00473, D08416 D08416 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
224 [1] 224 💬 |
240 |
Prednisone or prednisolone |
Prednisolone |
[9] D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
241 |
Prednisone, methylprednisolone,cyclophosphamides |
Methylprednisolone |
[7] D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
042 [3] 42, 43, 45 💬 |
242 |
Prednisone/prednisolone |
Prednisolone |
[9] D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
035 [1] 35 💬 |
243 |
Procedure: epidural steroid (dexamethasone) injection |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
070 [1] 70 💬 |
244 |
Procedure: warm compress prior to injection of glatiramer acetate |
Acetate |
[1] D04318 D04318 💬 |
HLA-A [20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection [32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 [1] 13 💬 |
245 |
Pyridoxine plus prednisolone |
Prednisolone |
[10] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02179 D02179, D03301 D03301, D08454 D08454 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
145 [1] 145 💬 |
246 |
Sodium acetate |
Acetate |
[1] D01779 D01779 💬 |
- |
- |
081 [1] 81 💬 |
247 |
Sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate |
Acetate |
- |
- |
- |
046 [1] 46 💬 |
248 |
Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate |
Acetate |
- |
- |
- |
046 [1] 46 💬 |
249 |
Soluble prednisolone tablets |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
145 [1] 145 💬 |
250 |
Sotrastaurin (inn) acetate |
Acetate |
[1] D09671 D09671 💬 |
PRKCD [4] PRKCD, PRKCE, PRKCH, PRKCQ 💬 |
AGE-RAGE signaling pathway in diabetic complications [28] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Aldosterone synthesis and secretion, Apelin signaling pathway, Autophagy - animal, C-type lectin receptor signaling pathway, Chemokine signaling pathway, Diabetic cardiomyopathy, Estrogen signaling pathway, Fc gamma R-mediated phagocytosis, GnRH signaling pathway, Inflammatory mediator regulation of TRP channels, Insulin resistance, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Prion disease, Shigellosis, Sphingolipid signaling pathway, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
097 [1] 97 💬 |
251 |
Sulphasalazine + hydroxychloroquine or prednisolone |
Hydroxychloroquine |
[9] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D08050 D08050 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
252 |
Tesamorelin |
Tesamorelin |
[2] D06655 D06655, D09015 D09015 💬 |
GHRHR [1] GHRHR 💬 |
Growth hormone synthesis, secretion and action [2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
078 [2] 78, 265 💬 |
253 |
Tesamorelin (egrifta) |
Tesamorelin |
[2] D06655 D06655, D09015 D09015 💬 |
GHRHR [1] GHRHR 💬 |
Growth hormone synthesis, secretion and action [2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
265 [1] 265 💬 |
254 |
Tetracosactide acetate |
Acetate |
[1] D00284 D00284 💬 |
MC2R [1] MC2R 💬 |
Aldosterone synthesis and secretion [5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 [2] 83, 145 💬 |
255 |
Theophylline |
Theophylline |
[5] D00371 D00371, D01712 D01712, D02017 D02017, D06103 D06103, D06104 D06104 💬 |
ADORA1 [19] ADORA1, ADORA2A, ADORA2B, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B 💬 |
Alcoholism [24] Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
236 [2] 236, 299 💬 |
256 |
Theophylline er |
Theophylline |
[5] D00371 D00371, D01712 D01712, D02017 D02017, D06103 D06103, D06104 D06104 💬 |
ADORA1 [19] ADORA1, ADORA2A, ADORA2B, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B 💬 |
Alcoholism [24] Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
236 [1] 236 💬 |
257 |
Tocopherol acetate |
Acetate |
[1] D02332 D02332 💬 |
- |
- |
049 [1] 49 💬 |
258 |
Tocopheryl acetate |
Acetate |
- |
- |
- |
206 [1] 206 💬 |
259 |
Trexan+salazopyrin+oxiklorin+prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
260 |
Trexan+salazopyrin+oxiklorin+prednisolone + infliximab |
Infliximab |
[9] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02598 D02598, D03301 D03301 💬 |
NR3C1 [2] NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [66] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
261 |
Triptorelin acetate and gonadorelin acetate |
Acetate |
[5] D00988 D00988, D03267 D03267, D04361 D04361, D06247 D06247, D08027 D08027 💬 |
GNRHR [1] GNRHR 💬 |
GnRH signaling pathway [2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
076 [1] 76 💬 |
262 |
Ulipristal acetate |
Acetate |
[1] D09567 D09567 💬 |
PGR [1] PGR 💬 |
Breast cancer [4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
010 [1] 10 💬 |
263 |
Z102 (prednisolone and dipyridamole). |
Dipyridamole |
[9] D00302 D00302, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [3] NR3C1, PDE4A, PDE5A 💬 |
Metabolic pathways [7] Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 [1] 46 💬 |
264 |
Zinc acetate |
Acetate |
[1] D06408 D06408 💬 |
- |
- |
171 [2] 171, 299 💬 |
265 |
Zinc acetate (20mg/d) |
Acetate |
[1] D06408 D06408 💬 |
- |
- |
299 [1] 299 💬 |
266 |
Zinc acetate dihydrate |
Acetate |
[1] D06408 D06408 💬 |
- |
- |
171 [1] 171 💬 |
267 |
Zuretinol acetate |
Acetate |
- |
- |
- |
090 [1] 90 💬 |